Narcolepsy Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2032

The Narcolepsy market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Alkermes, Avadel Pharmaceuticals, Axsome Therapeutics, Inc., Centessa Pharmaceuticals, Cephalon Inc., ConSynance Therapeutics, Harmony Biosciences, Jazz Pharmaceuticals, KemPharm, NLS Pharmaceutics, Ono Pharma,Otsuka Pharmaceutical, Reset Therapeutics, Sunovion Pharmaceuticals, Suven Life Sciences, Takeda, Vallon Pharmaceuticals, XWPharma

[Nevada, United States] - DelveInsight's "Narcolepsy Market Insights, Epidemiology, and Market Forecast 2032." report offers a detailed examination of Narcolepsy, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Narcolepsy Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/report-store/narcolepsy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Narcolepsy Market Report:
The Narcolepsy market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2019-2032).
In September, 2024: Jazz Pharmaceuticals announced that the aim of their study is to quantify the change in blood pressure when participants with narcolepsy treated with high-sodium oxybate are transitioned to XYWAV, a low-sodium oxybate. The results of this study may provide health care providers (HCPs), patients, and payers with important new information regarding BP changes related to differences in sodium content between available oxybates for the treatment of narcolepsy.
In September, 2024: Takeda announces that the main aim of this study is to learn how effective TAK-861 is in improving excessive sleepiness during the day (called excessive daytime sleepiness or EDS) after 3 months of treatment.
In September, 2024: Alkermes, Inc. announced that their study will measure the safety and decrease in sleepiness in subjects with narcolepsy type 2 (NT2) when taking ALKS 2680 tablets compared to placebo tablets.
In July, 2024: Jazz Pharmaceuticals announced that their study will assess the safety and efficacy of JZP258 (XYWAV) on sleepiness, polysomnography, and functional outcomes in patients with idiopathic hypersomnia (IH) or narcolepsy.
According to Narcolepsy Network Organization, narcolepsy affects an estimated 1 in every 2,000 people in theUnited States. Narcolepsy is an under diagnosed sleep disorder which is most common among the adults ascompared to the pediatrics.
According to Slowik et al. (2022), the prevalence for narcolepsy type 1 is 14 per 100,000 people and 65.4 per100,000 people for narcolepsy type 2. Its prevalence is highest in the late teens to early twenties with a 50%greater female predominance in the US according to 2008─2010 data.
According to the European Narcolepsy Network (EU-NN) database(2016), narcolepsy with cataplexy is a rare disease with anestimated prevalence of 0.02% in European populations. The meanage of patients diagnosed with NT-1 was 42 years for women and 44 years for men
Key Narcolepsy Companies are as follows: Alkermes, Avadel Pharmaceuticals, Axsome Therapeutics, Inc., Centessa Pharmaceuticals, Cephalon Inc., ConSynance Therapeutics, Harmony Biosciences, Jazz Pharmaceuticals, KemPharm, NLS Pharmaceutics, Ono Pharma,Otsuka Pharmaceutical, Reset Therapeutics, Sunovion Pharmaceuticals, Suven Life Sciences, Takeda, Vallon Pharmaceuticals, XWPharma
Key Narcolepsy Therapies are as follow: JZP258, TS-091, SUVN-G3031, JNJ-17216498, Modafinil:, sodium oxybate, Modafinil + placebo, Modafinil, Mazindol, AXS-12 (Reboxetine), TAK-861, ALKS 2680, PF-0365474, FT218
Launching multiple stage Narcolepsy pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Narcolepsy market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/sample-request/narcolepsy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Narcolepsy Overview:
Narcolepsy is a chronic neurological/brain disorder which involves poor control of sleep and wakefulness.People suffering from narcolepsy experience periods of excessive daytime sleepiness and suddenuncontrollable episodes of falling asleep during any time of the day. Although the cause of narcolepsy is notcompletely understood, research suggests that narcolepsy may be a result of a combination of factors likeautoimmune disorders, family history, brain injuries, besides others.

Narcolepsy Epidemiology Segmentation:
The Narcolepsy market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
Narcolepsy Total Diagnosed Prevalent Cases
Narcolepsy Subtype-specific Diagnosed Prevalent Cases
Narcolepsy Age-specific Diagnosed Prevalent Cases
Narcolepsy Treated Cases in the 7mm

For more information about Narcolepsy companies working in the treatment market, visit https://www.delveinsight.com/sample-request/narcolepsy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Narcolepsy Market Insights
The global narcolepsy therapeutics market is projected to be valued at approximately USD 3.52 billion in 2023, with expectations to reach USD 6.01 billion by 2030. This translates to a compound annual growth rate (CAGR) of around 7.8%​
Organizations are actively promoting narcolepsy awareness, which is critical in driving diagnosis and treatment rates
Research and Development: Ongoing R&D efforts are crucial in introducing innovative therapies and improving treatment efficacy
Supportive Regulations: Favorable government policies and reimbursement frameworks facilitate patient access to necessary medications​

Narcolepsy Drugs Uptake
Sodium Oxybate: Dominates the market with a 46.70% share, largely due to high prescription rates and favorable reimbursement policies​
Central Nervous System Stimulants: Hold the second-largest share (around 33.85%) as they are commonly prescribed to enhance wakefulness in narcoleptic patients​
Novel Drugs: New therapies like WAKIX (pitolisant) and Lumryz have been recently approved, expanding treatment options and improving patient outcomes​
Narcolepsy with Cataplexy: Accounts for about 54.28% of the market, driven by the prevalence of cataplexy as a significant symptom​
Narcolepsy without Cataplexy: Expected to grow rapidly at a CAGR of 8.31% from 2023 to 2030, reflecting the rising awareness and diagnosis of type 2 narcolepsy​

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/narcolepsy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Narcolepsy Therapies and Key Companies:
JZP258: Jazz Pharmaceuticals
TS-091: Taisho Pharmaceutical Co., Ltd.
SUVN-G3031: Suven Life Sciences Limited
JNJ-17216498: Alza Corporation
Modafinil: Cephalon
sodium oxybate: Orphan Medical
Modafinil + placebo: Theranexus
Modafinil: Cephalon
Mazindol: NLS Pharmaceutics
AXS-12 (Reboxetine): Axsome Therapeutics, Inc.
TAK-861: Takeda
ALKS 2680: Alkermes, Inc.
PF-03654746: Pfizer
FT218: Avadel

Narcolepsy Epidemiology:
The narcolepsy market is experiencing significant growth, driven by increased awareness, advancements in drug therapies, and an expanding patient population. The global narcolepsy therapeutics market was valued at approximately USD 3.52 billion in 2023, and it's projected to reach USD 6.01 billion by 2030, reflecting a compound annual growth rate (CAGR) of 7.8%​.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/narcolepsy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Narcolepsy Market Drivers:
Increasing Awareness
R&D Investment
Regulatory Support

Narcolepsy Market Barriers:
High Cost of Treatment
Diagnostic Challenges

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/narcolepsy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Narcolepsy Market Report:
Study Period: 2019-2032
Coverage: 7MM (The United States, EU5, and Japan)
Key Narcolepsy Companies: Alkermes, Avadel Pharmaceuticals, Axsome Therapeutics, Inc., Centessa Pharmaceuticals, Cephalon Inc., ConSynance Therapeutics, Harmony Biosciences, Jazz Pharmaceuticals, KemPharm, NLS Pharmaceutics, Ono Pharma,Otsuka Pharmaceutical, Reset Therapeutics, Sunovion Pharmaceuticals, Suven Life Sciences, Takeda, Vallon Pharmaceuticals, XWPharma
Key Narcolepsy Therapies: JZP258, TS-091, SUVN-G3031, JNJ-17216498, Modafinil:, sodium oxybate, Modafinil + placebo, Modafinil, Mazindol, AXS-12 (Reboxetine), TAK-861, ALKS 2680, PF-0365474, FT218
Narcolepsy Therapeutic Assessment: Current marketed and emerging therapies
Narcolepsy Market Dynamics: Narcolepsy Market drivers and Narcolepsy barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Narcolepsy Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Narcolepsy market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/narcolepsy-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1. Key Insights
2. Executive Summary of Narcolepsy
3. Competitive Intelligence Analysis for Narcolepsy
4. Narcolepsy: Market Overview at a Glance
5. Narcolepsy: Disease Background and Overview
6. Patient Journey
7. Narcolepsy Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Narcolepsy Unmet Needs
10. Key Endpoints of Narcolepsy Treatment
11. Narcolepsy Marketed Products
12. Narcolepsy Emerging Therapies
13. Narcolepsy: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Narcolepsy
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

List of Top Selling Market Research Reports in 2024

Surgical Energy Generators Market- https://www.delveinsight.com/report-store/surgical-energy-generators-market
Surgical Sealant Tissue Patch Market- https://www.delveinsight.com/report-store/surgical-sealant-tissue-patch-market
Surgical Stapling Devices Market- https://www.delveinsight.com/report-store/surgical-stapling-devices-market
Vital Sign Monitoring Devices Market- https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market
Syphilis Market- https://www.delveinsight.com/report-store/syphilis-market
Vitreoretinal Surgery Devices Market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
Pelvic Organ Prolapse Market- https://www.delveinsight.com/report-store/pelvic-organ-prolapse-market
Scoliosis Market- https://www.delveinsight.com/report-store/scoliosis-market
SGLT2 Inhibitors Market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
Urinary Catheters Market- https://www.delveinsight.com/report-store/urinary-catheters-market
Carcinoid Syndrome Market- https://www.delveinsight.com/report-store/carcinoid-syndrome-market
Cardiac Monitoring Devices Market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
Varicose Vein Treatment Devices Market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
Bone Growth Stimulators Market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Skin Neoplasms Market- https://www.delveinsight.com/report-store/skin-neoplasms-market
Thrombectomy Devices Market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
Novel Drug Delivery Devices Market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
Lymphedema Market- https://www.delveinsight.com/report-store/lymphedema-market
Artificial Disc Market- https://www.delveinsight.com/report-store/artificial-disc-market
Exocrine Pancreatic Insufficiency Market- https://www.delveinsight.com/report-store/exocrine-pancreatic-insufficiency-epi-market
Fabry Disease Market- https://www.delveinsight.com/report-store/fabry-disease-market
Overactive Bladder Market- https://www.delveinsight.com/report-store/overactive-bladder-oab-market
Total Knee Arthroplasty Market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
Hip Replacement Devices Market- https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
Lactose Intolerance Market- https://www.delveinsight.com/report-store/lactose-intolerance-market
HDAC Inhibitors Market- https://www.delveinsight.com/report-store/hdac-inhibitors-market
Ventral Hernia Market- https://www.delveinsight.com/report-store/ventral-hernia-market
Facial Lines Market- https://www.delveinsight.com/report-store/facial-lines-market
Medical Marijuana Market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight
Microscopy Device Market- https://www.delveinsight.com/report-store/microscopy-device-market

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.